HMA-EMA AI workplan and its 2 linked instruments
How to read this page
- First column: HMA-EMA AI workplan. The others are every document linked to it.
- Scroll sideways if there are more columns than fit.
- It does not compare content. It does not say which is stricter. Read the official texts for that.
| HMA-EMA AI workplan | EU AI Act | EMA AI reflection paper | |
|---|---|---|---|
| Authority | EMA | European Union | EMA |
| Legal weight | Guidance & Q&A | Law & regulation | Guidance & Q&A |
| Status | Final | Effective · phased | Final |
| Last verified | Not yet | Not yet | Not yet |
| Summary | Joint HMA and EMA workplan for artificial intelligence in medicines regulation, 2023 to 2028. It is a plan, not a requirement. | Horizontal EU law on AI systems, applying in phases. AI literacy duties already apply; transparency duties (Art. 50) apply from 2 August 2026. The 2026 digital omnibus moved high-risk obligations to December 2027 (Annex III) and August 2028 (Annex I, e.g. devices). | EMA's current thinking on AI and machine learning for human and veterinary medicines, covering principles that apply at any stage of a medicine's lifecycle, from drug discovery to after authorisation. |
| Lifecycle |
|
|
|
| Source | Official text Source: EMA. | Official text Source: European Union. Licensed under CC BY 4.0. | Official text Source: EMA. |
These facts are placed side by side from each record. This page does not say which is stricter or whether requirements differ. Read the official texts.